Pfizer's once-daily Lyrica met goal of trial in fibromyalgia
Nov 19 (Reuters) - Pfizer Inc said on Monday a late-stage trial of a once-daily version of its drug Lyrica in patients with fibromyalgia, a pain condition affecting more than 5 million Americans, met its main goal.
Patients taking once-daily Lyrica, also known as pregabalin, went for a significantly longer period of time before feeling pain compared with patients who took a placebo.
The study is the second of three late-stage trials testing a controlled-release version of the drug, which is currently given several times a day.
A trial of the controlled-release version of the drug in patients with certain types of seizures did not meet its main goal, Pfizer said.
The company is also studying the drug in patients with neuralgia.
- Putin dissolves state news agency, tightens grip on Russia media
- North Korea says Kim's powerful uncle dismissed for 'criminal acts'
- Thai PM calls snap election, protesters want power now |
- Record cold, ice grip U.S.; more snow to blanket East
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'